JP2022550316A - 修飾ｅｈｄ２ドメインを含む結合モジュール - Google Patents

修飾ｅｈｄ２ドメインを含む結合モジュール Download PDF

Info

Publication number
JP2022550316A
JP2022550316A JP2022518946A JP2022518946A JP2022550316A JP 2022550316 A JP2022550316 A JP 2022550316A JP 2022518946 A JP2022518946 A JP 2022518946A JP 2022518946 A JP2022518946 A JP 2022518946A JP 2022550316 A JP2022550316 A JP 2022550316A
Authority
JP
Japan
Prior art keywords
ehd2
domain
binding
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550316A5 (https=
Inventor
コンテルマン，ローラント
ザイフェルト，オリヴァー
Original Assignee
ウニヴェルズィテート シュトゥットガルト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルズィテート シュトゥットガルト filed Critical ウニヴェルズィテート シュトゥットガルト
Publication of JP2022550316A publication Critical patent/JP2022550316A/ja
Publication of JP2022550316A5 publication Critical patent/JP2022550316A5/ja
Priority to JP2025014991A priority Critical patent/JP2025081354A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022518946A 2019-09-25 2020-09-25 修飾ｅｈｄ２ドメインを含む結合モジュール Pending JP2022550316A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025014991A JP2025081354A (ja) 2019-09-25 2025-01-31 修飾ｅｈｄ２ドメインを含む結合モジュール

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19199639.6 2019-09-25
EP19199639 2019-09-25
PCT/EP2020/077008 WO2021058804A1 (en) 2019-09-25 2020-09-25 Binding modules comprising modified ehd2 domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025014991A Division JP2025081354A (ja) 2019-09-25 2025-01-31 修飾ｅｈｄ２ドメインを含む結合モジュール

Publications (2)

Publication Number Publication Date
JP2022550316A true JP2022550316A (ja) 2022-12-01
JP2022550316A5 JP2022550316A5 (https=) 2023-04-18

Family

ID=68109107

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022518946A Pending JP2022550316A (ja) 2019-09-25 2020-09-25 修飾ｅｈｄ２ドメインを含む結合モジュール
JP2025014991A Withdrawn JP2025081354A (ja) 2019-09-25 2025-01-31 修飾ｅｈｄ２ドメインを含む結合モジュール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025014991A Withdrawn JP2025081354A (ja) 2019-09-25 2025-01-31 修飾ｅｈｄ２ドメインを含む結合モジュール

Country Status (9)

Country Link
US (1) US20220372147A1 (https=)
EP (1) EP4034244A1 (https=)
JP (2) JP2022550316A (https=)
KR (1) KR20220071210A (https=)
CN (1) CN115066275A (https=)
AU (1) AU2020356407A1 (https=)
CA (1) CA3155725A1 (https=)
MX (1) MX2022003507A (https=)
WO (1) WO2021058804A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4454706A1 (en) 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
JP2019502694A (ja) * 2015-12-18 2019-01-31 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 二特異性抗体基幹

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2009303318B2 (en) * 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics
CA2785907A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013075027A2 (en) * 2011-11-17 2013-05-23 Emergent Product Development Seattle, Llc Anti-sil6xr complex binding domains and methods of use
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
BR112017009277A2 (pt) * 2014-11-14 2017-12-19 Procter & Gamble compostos de silicone
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
BR112019005001A2 (pt) * 2016-09-15 2019-06-04 Universität Stuttgart proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral
AU2018414456B2 (en) * 2018-03-22 2025-09-11 Universität Stuttgart Multivalent binding molecules
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
BR112022017048A2 (pt) * 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
JP2023521418A (ja) * 2020-04-10 2023-05-24 インビビド， インコーポレイテッド コロナウイルスｓタンパク質に特異的な化合物及びその使用
EP4228697A4 (en) * 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502694A (ja) * 2015-12-18 2019-01-31 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 二特異性抗体基幹
WO2018037092A1 (en) * 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENNICH, H. H. ET AL.: "RecName: Full=Immunoglobulin heavy constant epsilon; AltName: Full=Ig epsilon chain C region; AltNam", UNIPROTKB, JPN6024010679, 18 September 2019 (2019-09-18), ISSN: 0005587080 *
OLIVER SEIFERT ET AL.: ""Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecule", MABS, vol. 11, no. 5, JPN6024010681, 3 May 2019 (2019-05-03), pages 919 - 929, ISSN: 0005587078 *
OLIVER SEIFERT ET AL.: ""Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties"", MOLECULAR CANCER THERAPEUTICS, vol. 13, no. 1, JPN6024010680, 1 January 2014 (2014-01-01), pages 101 - 111, ISSN: 0005587079 *

Also Published As

Publication number Publication date
US20220372147A1 (en) 2022-11-24
EP4034244A1 (en) 2022-08-03
WO2021058804A1 (en) 2021-04-01
AU2020356407A1 (en) 2022-04-07
CN115066275A (zh) 2022-09-16
CA3155725A1 (en) 2021-04-01
JP2025081354A (ja) 2025-05-27
KR20220071210A (ko) 2022-05-31
MX2022003507A (es) 2022-04-25

Similar Documents

Publication Publication Date Title
JP7599427B2 (ja) 多量体
US12522663B2 (en) Multivalent binding molecules
KR102945438B1 (ko) 오프-표적 독성을 감소시키는 프로-항체
JP2025029067A (ja) 多量体、四量体および八量体
US12331109B2 (en) Antigen binding molecule formats
EP4090686A2 (en) Pro-antibody that reduces off-target toxicity
JP2025081354A (ja) 修飾ｅｈｄ２ドメインを含む結合モジュール
JP6919100B2 (ja) 新規多重特異的結合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250131